Evaluation of drug-drug interactions in hospitalized patients on medications for OUD
Introduction: Medications used to treat OUD have common metabolic pathways and pharmacodynamic properties that can lead to drug-drug interactions (DDIs) that may go unnoticed in the inpatient setting. The purpose of this study was to identify the frequency of DDIs between medications prescribed for...
Main Authors: | Olivia Berger, PharmD, Katherine Rector, PharmD, BCPS, Jacqueline Meredith, PharmD, BCPS, BCIDP, Jamielynn Sebaaly, PharmD, BCPS |
---|---|
Format: | Article |
Language: | English |
Published: |
American Association of Psychiatric Pharmacists
2021-07-01
|
Series: | Mental Health Clinician |
Subjects: | |
Online Access: | https://theijpt.org/doi/pdf/10.9740/mhc.2021.07.231 |
Similar Items
-
Microdose induction of buprenorphine-naloxone in a patient using high dose methadone: A case report
by: Menard Shannon PharmD, et al.
Published: (2021-11-01) -
Development and implementation of a physician-pharmacist collaborative practice model for provision and management of buprenorphine/naloxone
by: Lindsay M. Mailloux, PharmD, et al.
Published: (2021-01-01) -
Characterization of inpatient care for patients admitted to a psychiatric hospital with a home opioid prescription
by: Kei Takamura, PharmD, BCPS, BCPP, et al.
Published: (2023-03-01) -
Differentiating probable nitrofurantoin-induced drug fever from antipsychotic-induced hyperthermia in a patient receiving clozapine
by: Stephen B. Vickery, PharmD, BCPS, et al.
Published: (2022-06-01) -
Addition of a clinical pharmacist practitioner to an inpatient addiction triage team and related medication outcomes
by: Kim Ehrhard, PharmD, BCPP, et al.
Published: (2023-08-01)